LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Search

Heron Therapeutics Inc

Fermé

SecteurSoins de santé

0.82 -4.65

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.81

Max

0.86

Chiffres clés

By Trading Economics

Revenu

15M

-3M

Ventes

2.4M

41M

BPA

-0.02

Marge bénéficiaire

-7.278

Employés

128

EBITDA

13M

-792K

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+417.24% upside

Dividendes

By Dow Jones

Prochains Résultats

5 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-49M

169M

Ouverture précédente

5.47

Clôture précédente

0.82

Sentiment de l'Actualité

By Acuity

50%

50%

171 / 351 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Heron Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 mars 2026, 22:51 UTC

Résultats

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mars 2026, 21:40 UTC

Acquisitions, Fusions, Rachats

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mars 2026, 20:31 UTC

Résultats

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mars 2026, 23:49 UTC

Market Talk
Principaux Événements d'Actualité

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mars 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

18 mars 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mars 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mars 2026, 22:36 UTC

Résultats

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mars 2026, 22:24 UTC

Résultats

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mars 2026, 22:23 UTC

Résultats

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mars 2026, 22:23 UTC

Résultats

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mars 2026, 21:58 UTC

Résultats

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mars 2026, 21:55 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

18 mars 2026, 21:55 UTC

Market Talk
Résultats

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mars 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mars 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mars 2026, 21:00 UTC

Principaux Événements d'Actualité

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mars 2026, 20:58 UTC

Résultats

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mars 2026, 20:41 UTC

Résultats

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mars 2026, 20:29 UTC

Résultats

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mars 2026, 20:25 UTC

Résultats

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mars 2026, 20:17 UTC

Résultats

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mars 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mars 2026, 20:09 UTC

Résultats

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mars 2026, 20:07 UTC

Résultats

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mars 2026, 20:06 UTC

Résultats

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mars 2026, 20:04 UTC

Résultats

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mars 2026, 20:04 UTC

Résultats

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mars 2026, 20:04 UTC

Résultats

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mars 2026, 20:03 UTC

Résultats

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Comparaison

Variation de prix

Heron Therapeutics Inc prévision

Objectif de Prix

By TipRanks

417.24% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  417.24%

Haut 6 USD

Bas 3 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

2.0001 / 2.42Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

171 / 351Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat